WaveMan
WaveMan · Company
EMMA · Emmaus Life Sciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

EMMA Emmaus Life Sciences (EMMA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000822370
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about EMMA

Insiders, 180 days
+$15.0K net bought
1 buyer

Emmaus Life Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Emmaus Life Sciences, Inc. insiders bought a net $15.0K of stock across 206 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
LEE WILLIS C
CEO
BUY
2026-09-02 SECtraded 2026-08-31
100,000
$5.0K
-24.8%
Context
  • 57 earlier Form 4 trades (code P or S) here by this insider (57 buys), the last on Aug 28, 2026.
  • -22.4% median (-27.3% mean) 90-day return after 27 previous buys.
  • The trade is 14.5% of the 690,167 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO LEE WILLIS C bought about $5.0K of EMMA on Aug 31, 2026.
LEE WILLIS C
CEO
BUY
2026-09-02 SECtraded 2026-08-28
94,767
$5.7K
-24.8%
Context
  • 56 earlier Form 4 trades (code P or S) here by this insider (56 buys), the last on Aug 27, 2026.
  • -22.1% median (-26.6% mean) 90-day return after 28 previous buys.
  • The trade is 16.1% of the 590,167 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO LEE WILLIS C bought about $5.7K of EMMA on Aug 28, 2026, the largest insider purchase at the company since 2024.
LEE WILLIS C
CEO
BUY
2026-09-02 SECtraded 2026-08-27
50,000
$2.5K
-24.8%
Context
  • 55 earlier Form 4 trades (code P or S) here by this insider (55 buys), the last on Aug 25, 2026.
  • -22.4% median (-26.8% mean) 90-day return after 29 previous buys.
  • The trade is 10.1% of the 495,400 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO LEE WILLIS C bought about $2.5K of EMMA on Aug 27, 2026, the largest insider purchase at the company since 2024.
LEE WILLIS C
CEO
BUY
2026-09-02 SECtraded 2026-08-25
46,000
$1.8K
-24.8%
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 buys), the last on Aug 29, 2025.
  • -22.1% median (-26.0% mean) 90-day return after 30 previous buys.
  • The trade is 10.3% of the 445,400 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO LEE WILLIS C bought about $1.8K of EMMA on Aug 25, 2026, the largest insider purchase at the company since 2024.
LEE WILLIS C
CEO
BUY
2026-09-02 SECtraded 2025-08-29
170,000
$1.7K
-24.8%
Context
  • 53 earlier Form 4 trades (code P or S) here by this insider (53 buys), the last on May 30, 2025.
  • -22.1% median (-25.9% mean) 90-day return after 30 previous buys.
  • The trade is 61.7% of the 275,400 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO LEE WILLIS C bought about $1.7K of EMMA on Aug 29, 2025, the largest insider purchase at the company since 2024.
206 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 201 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$15.0K over 180 days
+$15.0K over 90 days
more than 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-25.2% year over year
below 71% of Pharma & Biotech
Margin
-60.2% net margin
below 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch EMMA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+351.0%12M
-18%+226%+470%+714%2025-102025-122026-022026-042026-062026-082026-10 2026-08-28 · LEE WILLIS C bought $5.7K2026-08-31 · LEE WILLIS C bought $5.0K2026-08-27 · LEE WILLIS C bought $2.5K2026-08-25 · LEE WILLIS C bought $1.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns EMMA: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in EMMA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

EMMA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $15.0K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

EMMA financials

Revenue growth
-25.2%
XBRL, annual
Net margin
-60.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$15.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-38.8%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
0.16x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-30.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$25.4M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$12.5M$16.7M$29.6M$18.4M
Gross profit$11.6M$15.5M$28.3M$15.8M
Operating income$231.0K-$1.9M$3.5M-$6.6M
Net income-$7.5M-$6.5M-$3.7M-$10.6M
EPS (diluted)-0.12-0.10-0.07-0.21
Operating cash flow-$11.0K-$2.3M-$1.5M-$5.1M
Cash$2.1M$1.4M$2.5M$2.0M
Long-term debt$27.1M$29.0M$30.6M$30.4M
SEC XBRL, fiscal years, as known on 2026-10-28

EMMA Stock Sonar score 4/7 axes

Find similar shapesCompare

EMMA ranks highest on financial health (79th percentile) and risk and compliance (64th), and lowest on growth (29th), among Pharma & Biotech peers.

Financial health
79
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt0.16x · 79 pct, sector of 371
Growth
29
Inputs
  • Revenue growth, YoY-25.2% · 29 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
61
Inputs
  • Net Form 4 buying (codes P and S), 180d$15K · 66 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Risk and compliance
64
Inputs
  • Short interest, % of float+0.0% · 97 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+14.4% · 32 pct, sector of 511
3 not measured: Profitability, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

EMMA filings, in plain words

Are Emmaus Life Sciences insiders buying or selling EMMA?

In the 180 days to 2026-10-28, Emmaus Life Sciences insiders were net buyers, a net $15.0K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Emmaus Life Sciences insiders were net buyers of EMMA, a net $15.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies